查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1552573

美国兽医肿瘤市场规模、份额、趋势分析报告：按治疗方法、动物、癌症类型、细分市场预测，2024-2030 年

U.S. Veterinary Oncology Market Size, Share & Trends Analysis Report By Therapy (Surgery, Radiology, Chemotherapy, Immunotherapy), By Animal (Canine, Feline), By Cancer Type (Skin Cancer, Lymphoma, Sarcomas), And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

美国兽医肿瘤学市场的成长和趋势

Grand View Research, Inc.最新报告显示，预计到2030年，美国兽用肿瘤市场规模将达到10.8亿美元，2024年至2030年复合年增长率为10.76%。

宠物癌症盛行率不断上升、宠物饲主愿意为宠物花钱以及研究人员使用狗作为临床试验模型是推动市场成长的关键因素。此外，由于人们对宠物健康的日益关注，猫科动物癌症发病率的上升和宠物拥有量的增加预计也将刺激市场成长。此外，公司越来越多地采用併购、研究协议、联盟、伙伴关係、地理扩张和产品开发等策略来增强其市场地位。

例如，2020年11月，Virbac宣布核准Stelfonta，一种治疗犬肥大细胞肿瘤的新型肿瘤内注射疗法。 Elanco 也收购了 Aratana Therapeutics，用于其宠物药品管道。该公司还与 VetDC 签订了生产拉巴福嗪 (Tanovea) 的协议。此外，2021 年 7 月，Elanco 宣布 FDA 已完全核准Tanovea 用于治疗犬淋巴瘤。因此，预计市场在预测期内将出现激烈竞争。伴同性动物癌症盛行率的不断上升预计将推动对有效治疗方案的需求。

在狗中，骨癌是一种极具侵袭性的疾病，治疗方法包括化疗，可以降低手术切除肿瘤以及随后癌细胞扩散到其他部位（特别是肺部）的风险。据报道，金毛犬品种的癌症发生率比其他犬种更高。金毛猎犬是美国最受欢迎的犬种之一，人们对宠物健康的兴趣日益浓厚，推动了市场的成长。临床试验是兽医肿瘤学的一个重要方面。加速临床研究（包括宠物手术）正在进一步推动市场成长。

例如，2019年5月，奥勒冈州立大学进行的一项研究表明，肿瘤被完全切除的狗癌症復发的风险降低了60%。随着越来越多的美国养宠物，人们对动物健康的意识也越来越强。美国举办各种活动来传播宠物健康意识，其中包括国家宠物週。人们认为动物将 COVID-19 传播给个体的风险很小。 FDA 警告称，COVID-19 大流行可能会影响正在进行的开发新药研究。因此，2020年4月发布了指南，以减轻疫情对动物开发新药的潜在影响。

美国兽医肿瘤学市场报告亮点

  • 放射学领域预计将主导市场。政府加大倡议建立新的兽医放射中心和放射技术的进步等因素预计将支持该领域的成长。
  • 随着越来越多的兽医院专注于免疫治疗领域的临床试验，免疫治疗领域预计将在 2023 年至 2030 年实现最快的复合年增长率。
  • 预计到 2030 年，化疗将成为第二大治疗领域。据癌症兽医中心称，最常见的接受化疗的犬和猫肿瘤包括骨癌、淋巴瘤、血管肉瘤、肥大细胞肿瘤、膀胱肿瘤和乳腺肿瘤。
  • 2023 年，狗类细分市场占据了最大的收益占有率。狗的癌症高发病率和该领域持续的产品创新促进了该细分市场的成长。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章美国兽医肿瘤学市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/辅助市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
    • 市场机会分析
    • 市场问题分析
  • 美国兽医肿瘤学市场分析工具
    • 波特的分析
    • PESTEL分析
  • COVID-19 分析
  • 主要国家的宠物数量估计

第四章美国兽医肿瘤学市场：动物、估计与趋势分析

  • 细分仪表板
  • 美国兽医肿瘤市场波动分析
  • 2018-2030 年美国兽医肿瘤市场规模及趋势分析（以动物）
  • 狗
  • 猫
  • 马

第五章美国兽医肿瘤市场：治疗方法、估计与趋势分析

  • 细分仪表板
  • 美国兽医肿瘤市场波动分析
  • 2018-2030 年美国兽医肿瘤市场规模与趋势分析（依治疗方法）
  • 放射治疗
  • 外科手术
  • 化疗
  • 免疫疗法
  • 其他的

第六章美国兽医肿瘤市场：癌症类型、估计与趋势分析

  • 细分仪表板
  • 美国兽医肿瘤市场波动分析
  • 2018-2030 年美国兽医肿瘤学市场规模与趋势分析（依癌症类型）
  • 皮肤癌
  • 淋巴瘤
  • 肉瘤
  • 其他的

第七章 竞争格局

  • 市场参与企业分类
  • 企业市场分析/热图分析
  • 2023年企业市场占有率评估分析
  • 策略规划
    • 併购
    • 伙伴关係与协作
    • 其他的
  • 公司简介
    • Elanco
    • Boehringer Ingelheim International GmbH.
    • Zoetis
    • PetCure Oncology
    • Accuray Incorporated
    • Varian Medical Systems, Inc.
    • Elekta AB.
    • Karyopharm Therapeutics, Inc.
    • Virbac.
    • Merck &Co., Inc.
    • Dechra Pharmaceuticals PLC
    • NovaVive Inc.
    • Ardent Animal Health, LLC（A BreakthrU Company）.

第8章 要点

Product Code: GVR-4-68039-370-4

U.S. Veterinary Oncology Market Growth & Trends:

The U.S. veterinary oncology market size is expected to reach USD 1.08 billion by 2030, registering a CAGR of 10.76% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of cancer in pets, willingness to spend on them by pet owners, and use of canines as a model for clinical trials by researchers are the key contributing factor toward the market growth. In addition, a rise in the incidence of cancer in the feline population and rising pet ownership resulting in the increased focus on pet health is further expected to spur the growth. Moreover, companies are increasingly adopting strategies, such as M&As, research agreements, collaboration, partnerships, geographic expansion, and product development to enhance their market position.

For instance, in November 2020, Virbac publicized the approval of Stelfonta, a novel intratumoral injection treatment for canine mast cell tumors. In addition, Elanco purchased Aratana Therapeutics for its pet products pipeline. The company also had an agreement to create rabacfosadine (Tanovea), a drug from VetDC. In addition, in July 2021, Elanco proclaimed that the FDA granted full approval of Tanovea for the lymphoma treatment in dogs. Hence, the market is expected to witness intense competition over the forecast period. The growing prevalence of cancer in companion animals is expected to propel the need for effective treatment options.

In canines, appendicular osteosarcoma is an extremely aggressive illness and curative-intent treatment comprises surgical resection of the tumor followed by chemotherapy to diminish the risk of tumor cells spreading to other areas, particularly the lungs. The golden retriever breed has been reported to have a high cancer prevalence compared to others. Golden Retriever is one of the favorite breeds in the U.S. and increasing concerns regarding the wellbeing of pets are contributing to the market growth. Clinical trials are a critical aspect of veterinary oncology. The accelerated number of clinical research involving surgical procedures in pets is further fueling the market growth.

For instance, in May 2019, Oregon State University conducted a research study stating that the risk of cancer recurrence reduced to 60% in dogs whose tumors were completely resected. With the growing number of pet parents in the U.S., animal health awareness is rising among people. In the U.S., various pet health awareness events are conducted to spread awareness, such as National Pet Week. The risk of animals spreading COVID-19 to individuals is considered to be little. The FDA is alert that the COVID-19 pandemic may influence the ongoing studies being conducted to provision new animal drug development. Thereby, guidelines were issued in April 2020 to help diminish the potential impact of the pandemic on new animal drug development.

U.S. Veterinary Oncology Market Report Highlights:

  • The radiology segment is expected to dominate the market. Factors, such as increasing government initiatives for the establishment of new veterinary radiation centers and advancements in radiation technology, are expected to boost the segment growth
  • The immunotherapy segment is estimated to register the fastest CAGR from 2023 to 2030 owing to the growing number of veterinary centers focused on carrying out clinical trials in immunotherapy areas
  • Chemotherapy is estimated to be the second-largest therapy segment by 2030. According to the Cancer Veterinary Center, the most common canine & feline tumors treated with chemotherapy are osteosarcomas, lymphomas, hemangiosarcoma, mast cell tumors, bladder tumors, mammary gland tumors, etc.
  • The canine segment accounted for the largest revenue share in 2023. The high incidence of cancer in canines and ongoing product innovations in this domain contributed to the segment growth

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Scope
    • 1.1.2. Estimates And Forecast Timeline
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis
    • 1.6.2. Global Market: CAGR Calculation
  • 1.7. Research Scope and Assumptions
    • 1.7.1. List of Secondary Sources
    • 1.7.2. List of Primary Sources
    • 1.7.3. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Veterinary Oncology Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Drivers Analysis
      • 3.2.1.1. Increasing Prevalence Of Cancer In Pets
      • 3.2.1.2. Increasing R&D In Pet Cancer Therapy
      • 3.2.1.3. Growing Focus On Animal Safety
      • 3.2.1.4. Growing Uptake Of Pet Insurance
      • 3.2.1.5. Technological Advancements In Pet Cancer Treatment
      • 3.2.1.6. Increase In Pet Population
    • 3.2.2. Market Restraints Analysis
      • 3.2.2.1. High cost of treatment
      • 3.2.2.2. Adverse effects associated with therapies
      • 3.2.2.3. Limited Clinical Evidence
    • 3.2.3. Market Opportunity Analysis
    • 3.2.4. Market Challenges Analysis
  • 3.3. U.S. Veterinary Oncology Market Analysis Tools
    • 3.3.1. Porter's Analysis
      • 3.3.1.1. Bargaining power of the suppliers
      • 3.3.1.2. Bargaining power of the buyers
      • 3.3.1.3. Threats of substitution
      • 3.3.1.4. Threats from new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic and Social Landscape
      • 3.3.2.3. Technological landscape
      • 3.3.2.4. Environmental Landscape
      • 3.3.2.5. Legal landscape
  • 3.4. Covid-19 Analysis
  • 3.5. Estimated Pet Population, by key countries

Chapter 4. U.S. Veterinary Oncology Market: Animal Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Veterinary Oncology Market Movement Analysis
  • 4.3. U.S. Veterinary Oncology Market Size & Trend Analysis, by Animal, 2018 to 2030 (USD Million)
  • 4.4. Canine
    • 4.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.5. Feline
    • 4.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.6. Equine
    • 4.6.1. Market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. U.S. Veterinary Oncology Market: Therapy Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Veterinary Oncology Market Movement Analysis
  • 5.3. U.S. Veterinary Oncology Market Size & Trend Analysis, by Therapy, 2018 to 2030 (USD Million)
  • 5.4. Radiotherapy
    • 5.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.4.2. Stereotactic Radiation Therapy
      • 5.4.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.4.2.2. LINAC
        • 5.4.2.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.4.2.3. Other Type
        • 5.4.2.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.4.3. Conventional Radiation Therapy
      • 5.4.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5. Surgery
    • 5.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6. Chemotherapy
    • 5.6.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.7. Immunotherapy
    • 5.7.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.8. Other Therapies
    • 5.8.1. Market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. U.S. Veterinary Oncology Market: Cancer Type Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. Veterinary Oncology Market Movement Analysis
  • 6.3. U.S. Veterinary Oncology Market Size & Trend Analysis, by Cancer Type, 2018 to 2030 (USD Million)
  • 6.4. Skin Cancer
    • 6.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5. Lymphomas
    • 6.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.6. Sarcomas
    • 6.6.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.7. Others
    • 6.7.1. Market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Market Participant Categorization
  • 7.2. Company Market Position Analysis/ Heat Map Analysis
  • 7.3. Estimated Company Market Share Analysis, 2023
  • 7.4. Strategy Mapping
    • 7.4.1. Mergers & Acquisitions
    • 7.4.2. Partnerships & Collaborations
    • 7.4.3. Others
  • 7.5. Company Profiles
    • 7.5.1. Elanco
      • 7.5.1.1. Participant's Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Boehringer Ingelheim International GmbH.
      • 7.5.2.1. Participant's Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Zoetis
      • 7.5.3.1. Participant's Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. PetCure Oncology
      • 7.5.4.1. Participant's Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Accuray Incorporated
      • 7.5.5.1. Participant's Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Varian Medical Systems, Inc.
      • 7.5.6.1. Participant's Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Elekta AB.
      • 7.5.7.1. Participant's Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Karyopharm Therapeutics, Inc.
      • 7.5.8.1. Participant's Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Virbac.
      • 7.5.9.1. Participant's Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. Merck & Co., Inc.
      • 7.5.10.1. Participant's Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Strategic Initiatives
    • 7.5.11. Dechra Pharmaceuticals PLC
      • 7.5.11.1. Participant's Overview
      • 7.5.11.2. Financial Performance
      • 7.5.11.3. Product Benchmarking
      • 7.5.11.4. Strategic Initiatives
    • 7.5.12. NovaVive Inc.
      • 7.5.12.1. Participant's Overview
      • 7.5.12.2. Financial Performance
      • 7.5.12.3. Product Benchmarking
      • 7.5.12.4. Strategic Initiatives
    • 7.5.13. Ardent Animal Health, LLC (A BreakthrU Company).
      • 7.5.13.1. Participant's Overview
      • 7.5.13.2. Financial Performance
      • 7.5.13.3. Product Benchmarking
      • 7.5.13.4. Strategic Initiatives

Chapter 8. Key Takeaways

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 U.S. Veterinary Oncology Market, by Animal, 2018 - 2030 (USD Million)
  • Table 4 U.S. Veterinary Oncology Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 5 U.S. Veterinary Oncology Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 6 Company Overview
  • Table 7 Service Benchmarking
  • Table 8 Financial Performance
  • Table 9 Strategic Initiatives

List of Figures

  • Fig. 1 U.S. Veterinary Oncology Market Segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Data Analysis Models
  • Fig. 6 Market Formulation And Validation
  • Fig. 7 Data Validating & Publishing
  • Fig. 8 General methodology for a commodity flow analysis of U.S. Veterinary Oncology Market
  • Fig. 9 Commodity flow analysis
  • Fig. 10 Parent market analysis
  • Fig. 11 Market Snapshot
  • Fig. 12 Segment snapshot
  • Fig. 13 Segment snapshot
  • Fig. 14 Competitive landscape snapshot
  • Fig. 15 Parent market value, 2023 (USD Billion)
  • Fig. 16 Ancillary market outlook, 2023
  • Fig. 17 U.S. Veterinary Oncology Market Dynamics
  • Fig. 18 Estimated animal population, 2018-2023 by key species and key countries
  • Fig. 19 U.S. Veterinary Oncology Market: PORTER's analysis
  • Fig. 20 U.S. Veterinary Oncology Market: PESTEL analysis
  • Fig. 21 U.S. Veterinary Oncology Market by Animal: Key Takeaways
  • Fig. 22 U.S. Veterinary Oncology Market by Animal, 2023 & 2030
  • Fig. 23 Canine market, 2018 - 2030 (USD Million)
  • Fig. 24 Feline market, 2018 - 2030 (USD Million)
  • Fig. 25 Equine market, 2018 - 2030 (USD Million)
  • Fig. 26 Horses market, 2018 - 2030 (USD Million)
  • Fig. 27 U.S. Veterinary Oncology Market by Therapy: Key Takeaways
  • Fig. 28 U.S. Veterinary Oncology Market by Therapy, Market Share, 2023 & 2030
  • Fig. 29 Radiotherapy market, 2018 - 2030 (USD Million)
  • Fig. 30 Stereotactic Radiation Therapy market, 2018 - 2030 (USD Million)
  • Fig. 31 LINAC market, 2018 - 2030 (USD Million)
  • Fig. 32 Other Stereotactic Radiation Therapy market, 2018 - 2030 (USD Million)
  • Fig. 33 Conventional Radiation Therapy market, 2018 - 2030 (USD Million)
  • Fig. 34 Surgery market, 2018 - 2030 (USD Million)
  • Fig. 35 Chemotherapy market, 2018 - 2030 (USD Million)
  • Fig. 36 Immunotherapy market, 2018 - 2030 (USD Million)
  • Fig. 37 Other therapies market, 2018 - 2030 (USD Million)
  • Fig. 38 U.S. Veterinary Oncology Market by Cancer Type: Key Takeaways
  • Fig. 39 U.S. Veterinary Oncology Market by Cancer Type, Market Share, 2023 & 2030
  • Fig. 40 Skin Cancers market, 2018 - 2030 (USD Million)
  • Fig. 41 Lymphomas market, 2018 - 2030 (USD Million)
  • Fig. 42 Sarcomas market, 2018 - 2030 (USD Million)
  • Fig. 43 Other market, 2018 - 2030 (USD Million)
  • Fig. 44 Market Participant Categorization
  • Fig. 45 Heat map analysis
  • Fig. 46 Strategic Framework